Successful alternative vaccination with BNT162b2 mRNA COVID-19 vaccine for new-onset IgA vasculitis after receiving mRNA-1273—case report

Fumiyuki Morioka1 · Shinya Nakatani2 · Akihiro Tsuda2 · Katsuhito Mori3 · Masanori Emoto2,3

Received: 22 July 2022 / Accepted: 4 September 2022 / Published online: 17 September 2022
© The Author(s) under exclusive licence to The Japan Society of Nephrology 2022

To the Editor,

We previously presented the first known case of kidney biopsy-proven new-onset IgA vasculitis following vaccination with the mRNA-1273 (Moderna) coronavirus disease 2019 (COVID-19) vaccine [1]. Though rare, a wide variety of adverse events have been reported during vaccination campaigns conducted worldwide, including new-onset and recurrent cases of glomerulonephritis [2]. It remains unclear whether third and fourth vaccinations are safe for patients with glomerulonephritis that develops or shows a flare-up after receiving a COVID-19 vaccine. We present here follow-up findings of our previously reported case showing no development of symptoms related to IgA vasculitis or COVID-19 after receiving a third vaccination with BNT162b2 mRNA (Pfizer-BioNTech) COVID-19.

A 47-year-old male was presented with purpuric eruptions on the legs and dorsal regions of the feet at 19 days after receiving the first mRNA-1273 COVID-19 vaccination injection and again 15 days after the second injection. Twenty-eight days after that second vaccination, urinalysis results showed severe proteinuria and occult blood. Kidney biopsy results led to a diagnosis of newly developed IgA vasculitis after receiving a COVID-19 vaccination. The clinical course following the kidney biopsy is presented in Fig. 1. Intravenous methylprednisolone at 1000 mg was given for three days, after which oral prednisolone (50 mg/day) was prescribed, with kidney function and urinary protein improved during the following period. According to government policy, six months is the recommended interval between the second and third vaccination. At 235 days after the second vaccination, oral prednisolone was tapered to 7.5 mg/day, without IgA vasculitis flare-up. The patient wished to receive a third vaccination to avoid COVID-19 infection and the BNT162b2 mRNA COVID-19 vaccine was selected for that. Fortunately, there has been no recurrence of IgA vasculitis nor COVID-19 infection since that time.

The number of COVID-19 cases worldwide remains high and a seventh wave of infections has recently developed in Japan. It has reported that individuals with glomerulonephritis had higher overall rates of mortality and acute kidney injury as compared to a control group [3]. Thus, additional vaccination is considered important for glomerulonephritis cases.

Immunosuppressive therapy is a concern for patients with glomerulonephritis. Previous study noted that following a second mRNA base COVID-19 vaccination, glucocorticoid monotherapy did not interfere with antibody acquisition for the SARS-CoV-2 S receptor-binding domain protein [4]. Furthermore, it should be noted that glucocorticoid use at higher doses (≥ 10 mg/day) is associated with severe disease and COVID-19-related death, and requires hospitalization [5]. Physicians must be careful when administering immunosuppressive therapy for glomerulonephritis patients in regard to possible COVID-19-associated events and antibody acquisition.

The lower amount of mRNA contained in the BNT162b2 mRNA as compared to the mRNA-1273 vaccine might be a factor contributing to lack of IgA vasculitis developing in the present patient. Additionally, the possibility that oral prednisolone administration suppressed IgA vasculitis flare-up cannot be excluded. Nevertheless, administration of the
BNT162b2 mRNA COVID-19 vaccine as an alternative to mRNA-1273 COVID-19 was successful. Additional case reports and investigations are needed to confirm the efficacy and safety of alternative vaccination options for patients with glomerulonephritis.

Declarations

Conflict of interest The authors have declared that no conflict of interest exists.

Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent Written informed consent was obtained from the patient for the publication of his clinical data.

References

1. Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, et al. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022;11(3):358–62.
2. Klomjit N, Alexander MP, Fervenza FC, Zoghby Z, Garg A, Hogan MC, et al. COVID-19 vaccination and glomerulonephritis. Kidney Int Rep. 2021;6(12):2969–78.
3. Waldman M, Soler MJ, Garcia-Carro C, Lightstone L, Turner-Stokes T, Griffith M, et al. Results from the iRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney Int. 2021;99(1):227–37.
4. Ruddy JA, Connolly CM, Boyarsky BJ, Werbel WA, Christopher-Stine L, Garonzik-Wang I, et al. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(10):1351–2.
5. Stevens KI, Frangou E, Shin JI, Anders HJ, Bruchfeld A, Schonermarck U, et al. Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from ERA-IWG and EUVAS. Nephrol Dial Transplant. 2022;37(8):1400.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.